New antimicrobial molecules and new antibiotic strategies

Seminars in Respiratory and Critical Care Medicine

Volumn 30, Issue 2, 2009, Pages 161-171

  De Castro, Felipe Rodríguez ^a   Naranjo, Olga Rajas ^b   Marco, Javier Aspa ^b   Violán, Jordi Solé ^a  

^a HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Antibiotics; Community acquired pneumonia; New antimicrobials; Resistance; Treatment options

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; CEFDITOREN; CEFDITOREN PIVOXIL; CEPHALOSPORIN DERIVATIVE; DALFOPRISTIN PLUS QUINUPRISTIN; ERTAPENEM; FROPENEM; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; ICLAPRIM; KETOLIDE; LINEZOLID; LIPOPEPTIDE; MOXIFLOXACIN; NXL 103; OXAZOLIDINONE DERIVATIVE; PEFLOXACIN; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RANBEZOLID; STREPTOGRAMIN; TEICOPLANIN; TELITHROMYCIN; TOSUFLOXACIN; TROVAFLOXACIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC THERAPY; COMMUNITY ACQUIRED PNEUMONIA; DRUG INDICATION; DRUG RESEARCH; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

ACETAMIDES; ANTI-INFECTIVE AGENTS; BETA-LACTAMS; CEPHALOSPORINS; COMMUNITY-ACQUIRED INFECTIONS; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FLUOROQUINOLONES; HUMANS; KETOLIDES; LIPOPEPTIDES; OXAZOLIDINONES; PNEUMONIA, BACTERIAL; PRACTICE GUIDELINES AS TOPIC;

EID: 63149162797     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0029-1202935     Document Type: Review

References (72)

1. Coates ARM, Hu Y. Novel approaches to developing new antibiotics for bacterial infections. Br J Pharmacol 2007;152:1147-1154
2. Waldor MK. Disarming pathogens: a new approach for antibiotic development. N Engl J Med 2006;354:296-297
3. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the management of Community-Acquired Pneumonia. Clin Infect Dis 2007;44:S27-S72
4. Felmingham D, Reinert RR, Hirakata Y, Rodloff A. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother 2002;50(Suppl S1):25-37
5. Bosso JA. The antimicrobial armamentarium: evaluating current and future treatment options. Pharmacotherapy 2005;25(10 Pt 2):55S-62S
6. Khardori N. Antibiotics - Past, present, and future. Med Clin North Am 2006;90:1049-1076
7. Fagon J, Patrick H, Haas DW, et al. Treatment of gram-positive nosocomial pneumonia: prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Am J Respir Crit Care Med 2000;161:753-762
8. Hershberger E, Donabedian S, Konstantinou K, Zervos MJ. Quinupristin-dalfopristin resistance in gram-positive bacteria: mechanism of resistance and epidemiology. Clin Infect Dis 2004;38:92-98
9. Paterson DL. Clinical experience with recently approved antibiotics. Curr Opin Pharmacol 2006;6:486-490
10. Owens RC Jr, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005;41(Suppl 2):S144-S157
11. Van Bambeke F, Reinert RR, Appelbaum PC, Tulkens PM, Peetermans WE. Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options. Drugs 2007;67:2355-2382
12. Zhanel GG, Fontaine S, Adam H, et al. A review of new fluoroquinolones: focus on their use in respiratory tract infections. Treat Respir Med 2006;5:437-465
13. Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG. Clinical cure and survival in gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004;30:388-394
14. Wilcox MH. Efficacy of linezolid versus comparator therapies in gram-positive infections. J Antimicrob Chemother 2003;51(Suppl 2):ii27-ii35
15. San Pedro GS, Cammarata SK, Oliphant TH, Todisco T. Linezolid versus ceftriaxone/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia. Scand J Infect Dis 2002;34:720-728
16. Potoski BA, Adams J, Clarke L, et al. Epidemiological profile of linezolid-resistant coagulase-negative staphylococci. Clin Infect Dis 2006;43:165-171
17. Lodise TP, Kinzig-Schippers M, Drusano GL, et al. Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid. Antimicrob Agents Chemother 2008;52:1945-1951
18. Ortiz-Ruiz G, Vetter N, Isaacs R, Carides A, Woods GL, Friedland I. Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies. J Antimicrob Chemother 2004;53(Suppl 2):ii59-ii66
19. Alfageme I, Aspa J, Bello S, et al. Normativas para el diagnóstico y el tratamiento de la neumonía adquirida en la comunidad. Sociedad Española de Neumología y Cirugía de Tórax. Arch Bronconeumol 2005;41:272-289
20. American Thoracic SocietyInfectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416
21. Schmidt-Ioanas M, de Roux A, Lode H. New antibiotics for the treatment of severe staphylococcal infection in the critically ill patient. Curr Opin Crit Care 2005;11:481-486
22. Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modelling and clinical impact. J Infect Dis 2005;191:2149-2152
23. Lonks JR, Goldmann DA. Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections. Clin Infect Dis 2005;40:1657-1664
24. Wolter N, Smith AM, Low DE, Klugman KP. High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae. Antimicrob Agents Chemother 2007;51:1092-1095
25. Clay KD, Hanson JS, Pope SD, Rissmiller RW, Purdum PP III, Banks PM. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med 2006;144:415-420
26. Dore DD, Dibello JR, Lapane KL. Telithromycin use and spontaneous reports of hepatotoxicity. Drug Saf 2007;30:697-703
27. Van Bambeke F, Harms JM, Van Laethem Y, Tulkens PM. Ketolides: pharmacological profile and rational positioning in the treatment of respiratory tract infections. Expert Opin Pharmacother 2008;9:267-283
28. Doan TL, Fung HB, Mehta D, Riska PE. Tigecycline: a glycylcycline antimicrobial agent. Clin Ther 2006;28:1079-1106
29. Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis 2006;43:518-524
30. Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs 2007;67:1027-1052
31. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008;36:1089-1096
32. Réa-Neto A, Niederman M, Lobo SM, et al. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin 2008;24:2113-2126
33. Keam SJ, Perry CM. Prulifloxacin. Drugs 2004;64:2221-2234
34. Blasi F, Aliberti S, Tarsia P, Santus P, Centanni S, Allegra L. Prulifloxacin: a brief review of its potential in the treatment of acute exacerbation of chronic bronchitis. Int J Chron Obstruct Pulmon Dis 2007;2:27-31
35. Jones RN, Sader HS, Stilwell MG, Fritsche TR. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2007;58:1-7
36. Hammerschlag MR, Reznik T, Roblin PM, Ramírez J, Summersgill J, Bukofzer S. Microbiological efficacy of ABT-773 (cethromycin) for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. J Antimicrob Chemother 2003;51:1025-1028
37. Hammerschlag MR, Sharma R. Use of cethromycin, a new ketolide, for the treatment of community-acquired respiratory infections. Expert Opin Investig Drugs 2008;17:387-400
38. Anderson SD, Gums JG. Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin. Ann Pharmacother 2008;42:806-816
39. Nicholson SC, Strauss RS, Michiels B, Noel GJ. Efficacy of ceftobiprole for the treatment of severely ill patients with hospitalized community-acquired pneumonia [abstract]. Am J Respir Crit Care Med 2008;177:A677
40. Biek D, Ge Y, Sahm DF. Activity of ceftaroline against common respiratory-associated pathogens from a collection of recent US isolates [abstract]. Am J Respir Crit Care Med 2008;177:A677
41. Gettig JP, Crank CW, Philbrick AH. Faropenem medoxomil. Ann Pharmacother 2008;42:80-90
42. Lentino JR, Narita M, Yu VL. New antimicrobial agents as therapy for resistant gram-positive cocci. Eur J Clin Microbiol Infect Dis 2008;27:3-15
43. Attwood RJ, LaPlante KL. Telavancin: a novel glycolipopeptide antimicrobial agent. Am J Health Syst Pharm 2007;64:2335-2348
44. Van Bambeke F, Van Laethem Y, Courvalin P, Tulkens PM. Glycopeptide antibiotics: from conventional molecules to new derivatives. Drugs 2004;64:913-936
45. Kohlhoff SA, Sharma R. Iclaprim. Expert Opin Investig Drugs 2007;16:1441-1448
46. Guay DR. Drug forecast: the peptide deformylase inhibitors as antibacterial agents. Ther Clin Risk Manag 2007;3:513-525
47. Menéndez R, Torres A, Zalacain R, et al. Guidelines for the treatment of community-acquired pneumonia: predictors of adherence and outcome. Am J Respir Crit Care Med 2005;172:757-762
48. Menéndez R, Torres A, Rodríguez de Castro F, et al. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis 2004;39:1783-1790
49. Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care process, and outcomes in elderly patients with pneumonia. JAMA 1997;278:2080-2084
50. Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004;164:637-644
51. Berjohn CM, Fishman NO, Joffe MM, Edelstein PH, Metlay JP. Treatment and outcomes for patients with bacteremic pneumococcal pneumonia. Medicine 2008;87: 160-166
52. Kanwar M, Brar N, Khatib R, Fakih MG. Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics: side effects of the 4-h antibiotic administration rule. Chest 2007;131:1865-1869
53. Waterer GW, Kessler LA, Wunderink RG. Delayed administration of antibiotics and atypical presentation in community-acquired pneumonia. Chest 2006;130:11-15
54. Schaaf B, Kruse J, Rupp J, et al. Sepsis severity predicts outcome in community-acquired pneumococcal pneumonia. Eur Respir J 2007;30:517-524
55. Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978-1997. Am J Med 1999;107:34S-43S
56. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001;161:1837-1842
57. Martinez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003;36:389-395
58. Lodise TP, Kwa A, Cosler L, Gupta R, Smith R. Comparison of β-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia. Antimicrob Agents Chemother 2007;51:3977-3982
59. Paul M, Nielsen AD, Gafter-Gvili A, et al. The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis. Eur Respir J 2007;30:525-531
60. Mouton JW, Vinks AA. Continuous infusion of beta-lactams. Curr Opin Crit Care 2007;13:598-606
61. File TM. The development of pharmacokinetically enhanced amoxicillin/clavulanate for the management of respiratory tract infections in adults. Int J Antimicrob Agents 2007;30(Suppl 2):S131-S134
62. Swainston Harrison T, Keam SJ. Azithromycin extended release: a review of its use in the treatment of acute bacterial sinusitis and community-acquired pneumonia in the US. Drugs 2007;67:773-792
63. Li JZ, Winston LG, Moore DH, Bent S. Efficacy of short course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med 2007;120:783-790
64. el Moussaoui R, de Borgie CAJM, van den Broek P, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community-acquired pneumonia: randomised, double blind study. BMJ 2006;332:1355-1360
65. Anderson VR, Perry CM. Levofloxacin: a review of its use as a high-dose, short-course treatment for bacterial infection. Drugs 2008;68:535-565
66. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia. Am J Respir Crit Care Med 2006;174:84-93
67. Oosterheert JJ, Bonten MJM, Schneider MME, et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. BMJ 2006;333:1193-1197
68. Nathan RV, Rhew DC, Murray C, Bratzler DW, Houck PM, Weingarten SR. In-hospital observation after antibiotic switch in pneumonia: a national evaluation. Am J Med 2006;119:512.e1-512.e7
69. Carratalà J, García-Vidal C. What is healthcare-associated pneumonia and how is it managed? Curr Opin Infect Dis 2008;21:168-173
70. Niederman MS. Recent advances in community-acquired pneumonia: inpatient and outpatient. Chest 2007;131:1205-1215
71. Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008;46(Suppl 5):S378-S385
72. Micek ST, Dunne M, Kollef MH. Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production. Chest 2005;128:2732-2738